Patients with type 2 diabetes and slow gastric emptying at baseline may benefit more from treatment with long-acting GLP-1 receptor agonists, while in those with preserved gastric emptying, short-acting GLP-1 receptor agonists may be preferable. Here, GLP1R is linked to type 2 diabetes mellitus.